Stocks and Investing Stocks and Investing
Wed, June 1, 2022

Jason McCarthy Upgraded (VRTX) to Strong Buy and Held Target at $325 on, Jun 1st, 2022


Published on 2024-10-27 21:22:26 - WOPRAI, Jason McCarthy
  Print publication without navigation


Jason McCarthy of Maxim Group, Upgraded "Vertex Pharmaceuticals Incorporated" (VRTX) to Strong Buy and Held Target at $325 on, Jun 1st, 2022.

Jason has made no other calls on VRTX in the last 4 months.



There are 11 other peers that have a rating on VRTX. Out of the 11 peers that are also analyzing VRTX, 6 agree with Jason's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • David Risinger of "SVB Leerink" Initiated at Hold and Held Target at $265 on, Monday, May 23rd, 2022
  • Do Kim of "Piper Sandler" Maintained at Hold with Decreased Target to $242 on, Friday, May 6th, 2022
  • Brian Abrahams of "RBC Capital" Maintained at Hold with Decreased Target to $267 on, Friday, May 6th, 2022
  • Brian Skorney of "Baird" Downgraded from Buy to Hold on, Friday, May 6th, 2022
  • Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $240 on, Thursday, May 5th, 2022
  • Matthew Harrison of "Morgan Stanley" Upgraded from Sell to Hold and Held Target at $250 on, Tuesday, May 3rd, 2022


These are the ratings of the 5 analyists that currently disagree with Jason


  • Liisa Bayko of "Evercore ISI Group" Maintained at Buy and Held Target at $278 on, Tuesday, May 24th, 2022
  • Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $305 on, Friday, May 6th, 2022
  • Gena Wang of "Barclays" Maintained at Buy and Held Target at $291 on, Thursday, May 5th, 2022
  • Colin Bristow of "UBS" Maintained at Strong Buy with Decreased Target to $322 on, Wednesday, April 27th, 2022
  • Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $350 on, Monday, April 4th, 2022
Contributing Sources